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Nature Chemistry that reported on the number of nanoparticles contained within individual cells. This approach provided a way to analyse quantitatively the expression of mRNA sequences in cultured cancer cells and circulating tumour cells found in patient samples.
Single-cell mRNA cytometry based on intracellular assembly of magnetic clusters. Our approach to mRNA cytometry at the single-cell level is based on magnetic capture of cells using iron oxide nanoparticles functionalized with DNA capture probes complementary to an mRNA sequence of interest (Fig. 1a) . The capture probes are designed to be specific for a target mRNA. To allow the nanoparticles to penetrate the cells, cells are fixed, permeabilized and then incubated with the particles.
We found that the use of single nanoparticle-tethered capture probes was not sufficient for high levels of magnetic capture. In proof-of-concept studies monitoring the capture efficiency of a model cell line, low capture efficiencies were observed when a single capture probe was used (Fig. 1b) .
In contrast, when a combination of two capture probes were used, capture efficiency increased significantly. Dynamic light scattering measurements revealed that combining the two capture probes produced large aggregates in the presence of the complementary target strand, indicating that the dual probe strategy triggered the self-assembly of large magnetic clusters. ( Fig. 1c and Supplementary  Fig. 2 ). These clusters are probably retained within the permeabilized cells, whereas the single nanoparticles could diffuse out of the cells even after binding a target sequence. TEM studies confirmed the presence of nanoparticle clusters within cells containing a target sequence (Fig. 1d ).
The cells bearing internalized MNPs are trapped within a fluidic device that features six zones exhibiting differing linear velocities to allow differential sorting of cells with varying levels of bound MNPs (Fig. 1e,f ). Because MNPs have low magnetic susceptibilities, the fluidic channel contains X-shaped microfabricated structures to create localized subzones of low flow velocity and favourable capture dynamics. The first zone has a high linear velocity and thus retains cells with high magnetic content because the retaining magnetic force overcomes the drag force created by the locally high flow velocity. The following five zones exhibit gradually reduced linear velocities (see Fig. 1f and Supplementary Information for simulation information). This design allows cells with high magnetic content (that is, high mRNA expression) to be trapped in the first zone, whereas cells with lower mRNA expression become trapped in later zones based on their mRNA level. This device design has been used to perform high-resolution qualitative profiling of extracellular proteins 29 ; however, this is the first report that applied this device to nucleic-acid-based capture.
Profiling of a mRNA sequence using single cell cytometry. In the first suite of experiments, we assessed the capture efficiency of a device designed to facilitate mRNA cytometry and its ability to sort cells bearing different numbers of MNPs. Cultured PC3 cells, a prostate cancer cell line, were labelled with two MNPs targeting the mRNA for survivin, a gene sequence that has been explored as a potential cancer biomarker. Survivin promotes cell division and suppresses apoptosis in many human cancers. The antiapoptotic effect is related to its ability to inhibit caspases either directly or indirectly 30 . The transcription of the survivin gene is higher in 
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tumours than in normal tissue and is often correlated with metastasis and poor prognosis in cancer patients 31 .
The cell trapping profiles obtained by targeting the survivin mRNA were visualized by immunostaining cells with epithelial markers (EpCAM, CK) and also by confirming the presence of well defined cell nuclei using the nuclear stain DAPI ( Fig. 2a ). CD45 was also included in the immunostaining protocol to enable the identification of white blood cells when whole blood samples were processed. When CP1 and CP2 were used separately, very low levels of cells were captured ( Fig. 2a) . A non-specific capture probe (NSP) was also used and did not produce significant levels of trapped cells. However, when CP1 and CP2 were used together, much higher levels of cells were observed in the capture device, and the cells were visualized primarily in the first zone of the capture device, indicating high levels of expression. The capture profile and efficiency were unaffected if the PC3 cells were spiked into whole blood. To provide a means of gauging the overall capture efficiency, capture was also carried out with an anti-EpCAM antibody (complementary to survivin mRNA), CP2 (complementary to survivin mRNA), a non-specific probe (NSP), and a combination of CP1 and CP2 in a buffer solution and blood. A control experiment was carried out in which PC3 cells were captured using magnetic nanoparticles tagged with anti-EpCAM. One hundred cells were used in these trials. The inset shows the immunostaining combination used to identify cancer cells. b, Cellular analysis of survivin mRNA in PC3, LNCaP, and VCaP cell lines. Two hundred cells were used in these trials. The curves represent the normal distribution fit to the capture data. The mRNA capture fraction reflects the capture using mRNA-targeted nanoparticles relative to those labelled with anti-EpCAM. c, Overall mRNA capture fraction for PC3, LNCaP, and VCaP cells, which compares the number of cells captured with mRNA-targeted nanoparticles versus anti-EpCAM targeted nanoparticles. d, Expression index, which reflects the mRNA capture fraction divided by the average capture zone. e, Survivin expression levels determined by RT-qPCR. f, EI Survivin in PC3 cells before and after silencing the survivin gene with LY2181308 siRNA. Two hundred cells were used in these trials. The curves represent the normal distribution fit to the data. g, Flow cytometric analysis of survivin protein in PC3 cells before and after silencing the survivin gene. Statistical analyses of data are provided in Supplementary Tables 8− 11 .
Nature Chemistry conjugated to MNPs. EpCAM is an epithelial marker found on the surface of tumour cells, and therefore is a standard protein marker to target particularly when cancer cells are isolated from blood. In all trials in which cellular mRNA was tagged with MNPs, a separate sample aliquot was analysed using anti-EpCAM to provide an overall cell or CTC count. Three prostate cancer cell lines (PC3, LNCaP and VCaP) were tested in parallel to compare capture efficiencies and the profiles collected using mRNA cytometry ( Fig. 2b, Supplementary Fig. 3 ). The cells were spiked into blood to ensure that heterogeneous samples were compatible with the approach. The number of cells captured using anti-EpCAM was compared to the number captured using the mRNA-directed approach to determine the overall mRNA capture fraction. For each of the cell lines tested, the overall, EpCAMmediated capture efficiencies were high (VCaP 92 ± 4%, LNCaP 95 ± 3%, PC3 92 ± 6%), but for the mRNA-targeted trials, the capture levels varied (VCaP 38 ± 11%, LNCaP 66 ± 9%, PC3 79 ± 8%), reflecting the varied expression of survivin in these cell lines. The comparison of the levels of capture when mRNA-targeting was used compared to EpCAM-targeting allowed us to estimate the capture fractions ( Fig. 2c ). Levels of nonspecific capture were taken into account in the calculation of capture fraction (see Supplementary  Information) . These studies were conducted with 200 cells spiked into one millilitre of blood; comparable results were obtained with 15 and 50 cells in the same volume ( Supplementary Fig. 4 ). While a low level of non-specific capture of white blood cells was observed ( Supplementary Fig. 5 ), these cells do not cause false positives because of their distinct staining profiles.
For each cell line, the median zone of capture was determined to provide a parameter that could be used to refine the calculation of relative RNA expression for the cell lines. The PC3 and LNCaP cells were primarily captured in the early zones of the device and had average zone values of 1.8 and 1.9, respectively. The VCaP cells, in addition to having a much lower overall capture efficiency, had a much larger average zone value of 4.5. An expression index (EI) for the survivin mRNA was then calculated for each cell line; values are shown in Fig. 2d . The EI was calculated by dividing the capture fraction by the average zone parameter as described in the Supplementary Information. For example, for PC3 cells, the average zone value is 1.8 (Fig. 2b) , and the overall mRNA-mediated capture efficiency relative to anti-EpCAM mediated capture is 0.79 (Fig. 2c ). The EI is therefore calculated to be 4.4 (Fig. 2d ). For VCaP cells the capture efficiency is 0.38 ( Fig. 2c ) and the average zone is 4.5 (Fig. 2b) . The EI is therefore calculated to be 0.84 ( Fig. 2b ).
RT-qPCR was performed using the same cell lines to evaluate the relative expression of survivin. TATA-box binding protein, TBP, was used as a standard, and the expression levels of survivin were compared to TBP for each cell line ( Fig. 2e ). The levels of expression measured using mRNA cytometry ( Fig. 2d ) and PCR ( Fig. 2e ) are comparable, indicating that the method offers a quantitative approach to monitoring gene expression. For example, the EI values for PC3 and VCaP calculated using single-cell mRNA cytometry are 4.4 and 0.84, respectively, and the relative expression levels measured using PCR are 5.5 and 1. The values measured using the two methods agree within measurement error. The concordance of our expression index measurements with PCR-based RNA quantitation provides support to the notion that mRNA cytometry is quantitative, which could not be assumed because cells with a given number of nanoparticles could settle in a number of different adjacent zones (see simulations in Supplementary Information). These results also support the notion that the uptake of magnetic nanoparticles by the different cell types does not influence the expression profiling capability of this mRNA-targeted approach.
We then proceeded to demonstrate the selectivity of the approach by analysing survivin mRNA in PC3 cells before and after silencing the survivin gene with a small interfering RNA (siRNA). PC3 cells were transfected with LY2181308, a previously characterized siRNA directed against survivin 32 . We found that the 
transfected PC3 cells exhibited lower EI survivin compared to control cells ( Fig. 2f and Supplementary Fig. 6 ). Flow cytometric analysis of the survivin protein revealed that the protein level decreased by ~83% (Fig. 2g) . The results corroborated the mRNA expression data obtained using our approach. In these measurements, the overall mRNA-mediated capture efficiency decreases, and the average capture zone also changes, consistent with siRNA knocking down expression. However, the cell capture performed using anti-EpCAM remains constant ( Supplementary Fig. 7) . Therefore, the cells not captured by targeting survivin mRNA are still visible in these trials and we can conclusively determine that RNA expression has decreased. The sensitivity and dynamic range of the mRNA cytometry approach was also assessed ( Supplementary Fig. 4 ). Analysis of as few as 10 cells in a millilitre of cells could be reproducibly achieved, and the EI values were constant between 10 and 500 cells. When 1,000 cells were analysed, the early zones of the device appeared to saturate and this effect then shifted the EI to lower values. However, most clinical specimens would not contain such a high cell count. Specimens-especially from early-stage cancer patients-could contain fewer than 10 cells, in which case a full 10 ml blood sample would need to be processed rather than the 1 ml samples utilized here. The throughput of the analysis-a sample can be processed in ~100 min (600 μ l hr -1 )-is suitable for clinical applications.
The performance of single-cell mRNA cytometry was benchmarked against flow cytometry and FISH in order to assess sensitivity relative to these methods. Cells stained ( Supplementary Fig. 5 ) with fluorescent probes and analysed using flow cytometry could be visualized at low cell counts when suspended in buffered solution, but when spiked into blood, over 1,000 cells were required for detection. Even after the depletion of red and white blood cells, residual cells caused a significant background signal that obscured the signal emitted from the RNA probes.
RNA FISH was performed on cells captured in the fluidic capture device (Fig. 1e ). Cells were incubated with probes with attached MNPs and fluorophores, and then their fluorescence was imaged after cell capture. The level of fluorescence was higher in the earlier zones than later zones, providing independent confirmation that the number of nanoparticles in cells captured in different zones differed.
Analysis of clinically relevant mRNAs in rare cells.
We used this approach to analyse three prostate-cancer-specific mRNAs, including full-length androgen receptor (AR-FL), AR splice variant 7 (AR-V7), and TMPRSS2/ERG in VCaP, LnCAP and PC3 cells. Notably, expression of the androgen receptor is considered a key oncogenic driver at various stages of prostate cancer development and progression 33 . AR-V7 mRNA is the most abundantly expressed variant that drives prostate cancer during androgen deprivation therapy 34 . It was recently identified as a predictive biomarker for the resistance to abiraterone and enzalutamide in metastatic castrate-resistant prostate cancer patients 35 . The TMPRSS2(Exon 1)/ ERG(Exon 4) fusion is the most frequent gene fusion in prostate cancer, appearing in about 50% of prostate cancer patients and representing 90% of all prostate cancer gene fusions 36 . In addition, the presence of TMPRSS2/ERG has been correlated with cancer aggression and metastatic potential 37 .
The expression pattern of each mRNA was analysed using our single-cell cytometry approach (Fig. 3, Supplementary Figs. 8-10 ). The EI was calculated for each mRNA (Fig. 3d) , and RT-qPCR was used to analyse the mRNAs in the three cell lines (Fig. 3e) . The two methods produced comparable profiles, again indicating that single-cell mRNA cytometry can be used to quantify gene expression levels. Supplementary Fig. 11 ) exhibited significantly higher expression indices than those that tested negative. c, Analysis of blood samples collected from prostate cancer patients for the androgen receptor splice variant AR-V7. Samples that tested positive for AR-V7 (see Supplementary Fig. 12 ) exhibited significantly higher expression indices than those that tested negative.
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To investigate whether the approach to mRNA analysis in CTCs offers an avenue to clinical utility, we analysed the TMPRSS2/ERG and AR-V7 mRNAs in blood samples collected from a small cohort of patients undergoing treatment for metastatic castration-resistant prostate cancer. An average of 12 ml of blood was analysed per patient and CTCs were identified using immunofluorescence and either mRNA-or EpCAM-based capture (Fig. 4) . Representative images of a CTC captured from patient samples versus a white blood cell are shown in Fig. 4a . A patient sample was considered positive for the target mRNA when the EI TMPRSS2/ERG was at least 1.5. Samples that tested positive for TMPRSS2/ERG or AR-V7 by mRNA cytometry exhibited significantly higher expression than those that tested negative as measured by PCR (Fig. 4b,c) .
In each analysis of a patient sample, the mRNA-based measurement was conducted along with a total CTC count obtained using anti-EpCAM-labelled beads. In 10 of the 11 patients tested, CTCs were visualized, but only 4 of the patients exhibited either of the targeted mRNAs. This mRNA analysis method, therefore can provide both a CTC count and information concerning the absence or presence of clinically relevant mRNAs.
In future, expanded studies of clinically relevant mRNAs will be needed to establish the detection algorithm for each sequence; however, the initial results presented herein support the idea that single-cell mRNA cytometry can report on the presence or absence of clinically relevant sequences in patient blood samples. The technique will also need to be tested on early-stage cancer patientswhose samples typically exhibit much lower levels of CTCs-to investigate its utility for non-metastatic patients.
Conclusions
The single-cell mRNA cytometry method described here provides a new amplification-free means of characterizing genotypes and gene expression patterns in intact, bloodborne cancer cells and is broadly applicable to other cell types. This approach relies on microscale clusters of magnetic nanoparticles formed in response to the presence of a specific mRNA inside human cells. Although the selforganization and sensing applications of many different types of nanoparticles have been studied [38] [39] [40] [41] [42] , our approach reports on the self-assembly of magnetic nanoparticles.
Although flow cytometry can be used to detect intracellular RNAs labelled with fluorescent probes, high cell numbers are required. The approach reported here allows the study of mRNA expression at the single-cell level. It is quantitative, and the expression levels measured using mRNA cytometry correlate closely with those measured using reverse transcription and enzymatic amplification. The method probes RNA levels directly rather than relying on serial enzymatic reactions and isolation steps. It is of interest in the analysis of specific mRNAs in CTCs that are relevant for therapeutic decision-making. Future improvements to the approach described here will be required to extend this method to the analysis of samples from patients with early-stage cancers, and to resolve bimodal populations of cells with differing expression levels.
Methods
Chip fabrication. Chips were fabricated using poly(dimethoxysilane) (PDMS, Dow Chemical, USA) soft-lithography. Masters were fabricated on silicon substrates and patterned in SU-8 3050 (Microchem, USA). Prior to use, devices were conditioned with 1% Pluronic F68 (Sigma-Aldrich, USA) in phosphatebuffered saline (PBS) for 1 h, to reduce the nonspecific adsorption. Each device was sandwiched between two arrays of N52 Nd FeB magnets (K&J Magnetics, USA, 1.5 mm by 8 mm) with alternating polarity.
Cell culture. VCaP cells (ATCC CRL-2876) were cultured in Dulbecco's modified Eagle's medium (DMEM, ATCC 30-2002) . PC3 cells were cultured in F-12K medium (ATCC . LNCaP cells were cultured in RPMI-1640 medium (ATCC 30-2001). All media were supplemented with 10% FBS and 1% penicillinstreptomycin and cells were cultured at 37 °C and 5% CO 2 in T75 flasks.
Preparation of the magnetic-nanoparticle-labelled capture probes. Briefly, 100 µ l of 20 µ M antisense oligonucleotide solution in Dulbecco's phosphatebuffered saline (DPBS, Sigma-Aldrich, USA), were heated for 5 min at 60 °C for deaggregation. The solution was transferred to a microtitre plate and incubated with 1.5 µ l of 10 mg ml −1 streptavidin-coated magnetic nanoparticles (100 nm, Chemicell, USA) for 30 min at room temperature. Subsequently, the magneticnanoparticle-labelled capture probes (MNPs-CPs) were pelleted using a magneticring stand (Thermofisher Scientific, USA) and washed three times with DPBS, containing 1 mM dithiothreitol (DPBS/DTT).
Cellular mRNA analysis. Cancer cells (200 cells in 100 µ l DPBS) were fixed with 100 µ l of 8% paraformaldehyde (PFA, Sigma-Aldrich, USA) solution in DPBS/DTT for 15 min at 37 °C. After centrifugation, the cells were incubated with 100 µ l of 0.3% Triton X-100 (TX-100, Sigma-Aldrich, USA) in DPBS/DTT for 10 min at room temp. Then, 100 µ l of labelled MNPs in DPBS/DTT were added and the suspension was gently shaken for 3 h at room temperature. The cells were loaded into the microfluidic device at a flow rate of 600 µ l h −1 .
Cell staining and imaging. Captured cells were counted using fluorescence microscopy. Prior to staining, captured cells were fixed inside the chip using 100 µ l of 4% PFA in DPBS/DTT followed by 100 µ l of 0.2% TX-100 in DPBS/ DTT for permeabilization. Captured cells were immunostained with a mixture of 3% allophycocyanin-labelled anti-cytokeratin antibody (APC-CK, GTX80205, Genetex, USA), 3% APC-labelled anti-EpCAM antibody (APC-EpCAM, Miltenyi Biotec, USA), and 3% Alexa Fluor 488-labelled anti-CD45 antibody (AF488-CD45, MHCD4520, Invitrogen, USA) in 100 µ l PBS containing 1% bovine serum albumin (BSA, Sigma-Aldrich, USA) and 0.1% Tween-20 (Sigma-Aldrich, US). Chips were scanned using a Nikon Ti-E Eclipse microscope with an automated stage controller and a CMOS Camera (Andor Neo).
Calculation of capture fraction and expression index.
The mRNA capture fraction is calculated from equation (1):
N CP denotes the number of cancer cells captured using the capture probe, N NSP represents the number of cells captured by the nonspecific probe, and N Ab is the total number of cells in the sample captured by anti-EpCAM. The percentage of cells captured in each zone is multiplied by the mRNA capture fraction to demonstrate the distribution of cell populations bearing different mRNA expression levels and generate a normal distribution fit from which the average capture zone (Zone Ave ) is determined.
The mRNA expression index (EI mRNA ) can then be calculated from equation (2) Tables S2-S20 and Figures 1-4 , S3-S5, and S7-S10
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